LEADERSHIP TEAM

Kurt Graves*

Chairman, President and CEO

Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Chairman of the company since August 2010 and as Acting CEO since October 2011. He is a global industry leader with more than twenty years of U.S. and global general management experience in top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals from 2007 through the end of 2009. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. In addition to Intarcia, Mr. Graves serves as Chairman of the Board of Radius therapeutics and as a Director at Springleaf Therapeutics and Pulmatrix Pharmaceuticals. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.

James Ahlers*

Vice President, Finance and Operations
Chief Financial Officer

Mr. Ahlers joined Intarcia Therapeutics in March 2000. Mr. Ahlers has served as a financial consultant to public and private biotechnology companies including Cytokinetics, GeneSoft and Tularik. He has extensive experience financing and building the infrastructure of growing pharmaceutical and biotechnology companies. In this capacity, Mr. Ahlers has served as the Director of Finance and Administration and managed the initial public offerings of Ansan Pharmaceuticals and Titan Pharmaceuticals. Previously, he was a member of the audit department in the San Francisco office of Deloitte & Touche and manager of Financial Planning and Analysis at Medco Behavioral Care Corporation. Mr. Ahlers earned a B.S. degree from the University of San Francisco in accounting.

Thomas Alessi, Ph.D.*

Vice President, Development and Manufacturing

Dr. Alessi joined Intarcia in December 1997 as Executive Director, Regulatory Affairs and Drug Development and was promoted to Vice President, Development in February 2002 with responsibility for the areas of product development, project management, chemistry and manufacturing. Prior to joining Intarcia, Dr. Alessi served as the Senior Director, Regulatory Affairs, Quality Assurance and Project Management at Ansan Pharmaceuticals where he was responsible for successful IND filings and for managing five drug development programs with oversight of vendors for preclinical and clinical studies and manufacturing clinical supplies. Before joining Ansan, Dr. Alessi was Director of Regulatory Affairs and Quality Assurance at Glycomed, Inc. where his duties included oversight and compliance of clinical manufacturing. His previous experience includes regulatory affairs and drug discovery experience in large pharmaceutical companies. Dr. Alessi was Senior Manager of Regulatory Affairs for Schering-Plough working in the Anti-infectives, Allergy Products and Chemisty, Manufacturing, & Controls groups. While at Schering-Plough, Dr. Alessi had regulatory responsibilities for approval and launch of interferon alfa-2b for hepatitis C as well as for hepatitis B. In his CMC role, he served on separate committees for process development and production of solid oral dosage forms, inhaled products, creams and semisolid products and sterile dosage forms, in addition to regulatory review of the CMC sections of Schering-Plough INDs and NDAs. Prior to joining Schering-Plough, Dr. Alessi invented and patented several new families of antidiabetic drugs while working as a Senior Scientist in the drug discovery group at Wyeth-Ayerst. Dr. Alessi earned a B.S. degree at Allegheny College and an M.S. and a Ph.D. in organic synthetic chemistry from the University of Rochester.

Michelle Baron, M.D., FACE*

Vice President, Clinical Research
Chief Medical Officer

Dr. Baron joined Intarcia in March 2012 as Vice President, Clinical Research and Chief Medical Officer. Dr. Baron is recognized throughout the industry as an accomplished physician in clinical drug development and medical affairs with deep expertise in cardiovascular, endocrinology and metabolic diseases. Prior to joining Intarcia, Dr. Baron was Vice President, Diabetes U.S. at sanofi-aventis, where her responsibilities included the design and commercialization of a U.S. Diabetes Patient Solutions platform and the assessment of business development opportunities and strategic partnerships for the U.S. Diabetes Division. Prior to that, Dr. Baron spent ten years at Novartis, ending her tenure there as Senior Medical Director, Diabetes Section of the Cardiovascular and Metabolism U.S. Clinical Development and Medical Affairs group. There, she led the team responsible for the planning, execution, monitoring and safe conduct of phase 2-4 diabetes and cardiovascular clinical trials and was a core member of the team designing and executing the clinical development, registration and commercialization strategies for Galvus® (vildagliptin) for the treatment of type 2 diabetes. She previously served as Program Director of the Endocrinology and Metabolism Fellowship Program, the Director of the Osteoporosis Diagnostic Center, and Fellow at the SUNY Health Science Center at Brooklyn, and as an Attending Physician in the Department of Medicine at Kings County Medical Center. She continues to serve as an Assistant Professor in the Department of Medicine's Division of Endocrinology and Metabolism at SUNY. She received her M.D. from Howard University College of Medicine, her B.A. from The Johns Hopkins University and did her postgraduate training in Internal Medicine at Emory University. She is a Fellow of the American College of Endocrinologists, a Diplomate of the American Board of Endocrinology and Metabolism, and a Diplomate of the American Board of Internal Medicine.

David Franklin*

Vice President, Commercial Operations

Mr. Franklin joined Intarcia in March 2006 as Vice President, Commercial Operations. Prior to joining Intarcia, Mr. Franklin was Senior Vice President, US Business Unit and Acting Senior Vice President, Global Marketing for Idenix Pharmaceuticals. As head of the US Business from March 2005 through March 2006, Mr. Franklin developed and executed plans for the commercialization of telbivudine, an antiviral for the treatment of chronic hepatitis B, and built the US Business Unit, an organization comprising approximately 40 Medical, Marketing and Sales personnel. From June 2003 until March 2005, Mr. Franklin served as Vice President, Commercial Operations, leading the Idenix Global Marketing group, directing brand development for telbivudine and for a phase II hepatitis C drug candidate and leading commercial efforts to form a global co-promotion and licensing alliance with Novartis AG. Prior to these responsibilities, Mr. Franklin held positions of increasing responsibility with Idenix as Executive Director, Marketing and Corporate Communications and Director, Marketing and played key roles in multiple private and public financing transactions and in business development and licensing transactions. Prior to joining Idenix in 1998, Mr. Franklin was Senior Product Manager, HIV Products for Bristol-Myers Squibb Co. with responsibility for Zerit and Videx, two antiviral therapies for the treatment of HIV infection. Prior to joining the HIV Products Division, Mr. Franklin held sales and sales administration positions within the Bristol-Myers Squibb Oncology Division from 1990 to 1995, responsible for sales force support, incentive compensation and alliance management. Mr. Franklin received a BA from Gettysburg College in 1988.

Owen Hughes, Jr.*

Chief Business Officer and Head of Corporate Development

Mr. Hughes joined Intarcia in February 2013 as Chief Business Officer and Head of Corporate Development. Prior to Intarcia, Mr. Hughes served as Director at Brookside Capital, an multi-billion dollar hedge fund that falls under the Bain Capital umbrella. There, he co-managed all public and private healthcare investments including biotechnology, med-tech, and services. Prior to his tenure at Brookside, Mr. Hughes was Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments Company, a Co-founder and Partner at Triathlon Fund Management, an Investment Associate at Ziff Brothers Investments, an Assistant Vice President at Merrill Lynch/Morgan Stanley, where we provided sell-side coverage of specialty healthcare distributors, and a Financial Analyst in the healthcare group at PaineWebber. Mr. Hughes received B.A. from Dartmouth College, where he received All-Ivy Honors, Academic All-Ivy Honors and was a four-year Letterman on the Varsity Ice Hockey team.

Barbara McClung*

Vice President, General Counsel, Corporate Secretary

Ms. McClung joined Intarcia in February 2007. Prior to joining Intarcia, she was General Counsel, Senior Vice President and Corporate Secretary at Cygnus, Inc., a medical device company, from 1998 to 2006, where she was responsible for all legal functions, including corporate transactions, litigation, annual and periodic filings with the Securities and Exchange Commission, corporate compliance and board governance, intellectual property strategy and portfolio management, contracts, and employment law. While at Cygnus, Ms. McClung assisted in the negotiation and completion of the sale of the company's glucose monitoring assets to Animas Corporation/Animas Technologies LLC in March 2005, and then facilitated the corporate dissolution of the company thereafter. Her previous employment from 1990 to 1998 was with Chiron Corporation, as a Division Patent Counsel, responsible for the intellectual property portfolio of the Chiron Vaccines Division, including its subsidiaries in Italy and Germany. Prior to that, Ms. McClung was an associate at Townsend & Townsend, and a patent counsel at E.I. du Pont de Nemours & Co. She is a member of the California, Delaware and Pennsylvania bars, as well as being a registered patent attorney before the United States Patent and Trademark Office. Ms. McClung received a J.D. from the University of Pennsylvania Law School, as well as a B.A. from the University of California, San Diego, and an M.A. from the University of Pennsylvania.

Janice Dahms

Executive Director, Product Development

Ms. Dahms joined Intarcia Therapeutics in January 2005 as Senior Director, Product Development. Prior to joining Intarcia, she was Senior Director, Project Management at Abgenix, Inc. where she built the project management organization and designed processes to manage product development both internally and with development partners, to ensure integration of project strategies with corporate strategy, and to evaluate potential new projects. She has been instrumental in the leadership of individual development projects across a range of development stages (pre-IND through NDA and launch) and across a number of therapeutic areas (oncology, immunology, central nervous system and endocirne disorders). She has extensive experience in both project management and clinical operations, and during her two-decade career in pharmaceutical development has held positions of increasing responsibility at Abgenix, ALZA, PAREXEL, and Bristol-Myers Squibb. Ms. Dahms is a graduate of Boston University and earned her M.S. in Pharmacology from the University of Chicago.

Dick Ford

Executive Director, DUROS® Manufacturing

Mr. Ford joined Intarcia as Executive Director, DUROS Manufacturing in August 2006. Prior to joining Intarcia, Mr. Ford held numerous positions during 16 years with Alza Corporation, with assignments in R&D, Advanced Development, Commercial Launch and Manufacturing. His last role there was Senior Director, Process Engineering. He has had extensive experience with various drug delivery platforms including transdermal, osmotic tablets, electrotransport and aseptic implants. During his time at Alza, Mr. Ford led a successful corporate Fast Cycle Time team effort to reduce clinical manufacturing time. He also directed all technical activities in the design, construction, startup and validation of an international greenfield transdermal commercial plant in Cashel, Ireland. Prior to Alza, Mr. Ford was employed at Raychem Corporation in Menlo Park, CA, where he held R&D, pilot plant scale-up, manufacturing engineering, and plant management roles within four different product divisions. Mr. Ford earned his B.S. in Chemical Engineering from Wayne State University.

Robert Lemmon, Ph.D.

Executive Director, Regulatory Compliance and Quality Assurance

Dr. Lemmon joined Intarcia in 2001 after a career of twenty years at Sanofi Pasteur. His work within the industry has spanned research, product development, manufacturing, regulatory affairs, and quality operations. During his career, he conducted research that led to the development of improved meningococcal, influenza, and pertussis vaccines, and the first protein-polysaccharide vaccine for the prevention of life threatening Hemophilus influenza disease in children. As Director of International Regulatory Affairs he built and managed systems to efficiently license and distribute vaccines worldwide. He has designed and implemented Quality System solutions that enhance productivity while assuring regulatory compliance throughout manufacturing operations. Dr. Lemmon earned his B.A. and M.S. degrees at Miami University and his Ph.D. in Microbiology at The University of Georgia. He pursued postdoctoral research within the Department of Biochemistry at Purdue University, and has held a position of Adjunct Professor in the School of Pharmacy at Temple University.

* Denotes Executive Officer of Intarcia